Call Us Toll Free: 1-800-388-9993

 

A reliable investment strategy: Identify a widely diversified portfolio of high-quality stocks and build up additional holdings at favorable prices.

 

DRIPs can help you do that.

 

Even small investors can follow such a strategy by investing through dividend reinvestment plans (DRIPs). That's because it takes ownership of only a single share of company stock to establish an account. Therefore, there is nothing to stop you from buying companies in a variety of industries.

 

As for buying at favorable prices, dollar-cost averaging virtually assures that you will buy most shares at favorable prices. And DRIPs provide an excellent way to dollar-cost average. These plans allow you to invest cash amounts to buy shares directly from the company. Once you are enrolled in a plan, you can invest amounts of as little as $25 or $50 (or many thousands of dollars) to buy shares or fractions of shares. That's different than the traditional way to invest, which is to pay brokerage fees to buy a certain number of shares.

 

 

AbbVie Inc. (ABBV)

Available from the Temper Enrollment Service: Yes


Last Update On: 07/18/2019:

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV) TECHNIVIE to treat adults with genotype 4 HCV infection and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency Synthroid to treat hypothyroidism and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease Sevoflurane, an anesthesia product and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc. Janssen Biotech, Inc. Galapagos Bristol-Myers Squibb Company and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.**Taken from Yahoo Finance**

Industry: Drugs, health care
Minimum Investment: $25.00
Maximum Investment: $150,000/year
Shares to qualify: 1
Recent Price: 68.54
Investing Fee: $0!
Fee for Dividends: $0!

! = Company pays fees

Information is based on an annual survey and updated when company changes become available.

Click for Español

FOR MORE
INFORMATION

And a free copy of The Moneypaper's direct investing brochure, please enter your contact information below.

You will also be signed up to receive our monthly stock special.

You can unsubscribe at any time. We do not share your email with anyone.

By email, you get the Monthly “Stock Special,” where the service fee for enrollment in a great DRIP stock is reduced.

* Required Field.